Standigm and CrystalGenomics announce partnership to discover novel therapeutics in cancer, rheumatoid arthritis and liver related diseases.

Updated:

Standigm, Inc. and CrystalGenomics, Inc. today agree collaborative partnership with the objective to discover and develop first-in-class drugs in the multiple therapeutic areas including cancer, rheumatoid arthritis and liver related diseases.

Tags: AI-driven drug discovery , Artificial Intelligence , Cancer , CrystalGenomics , Standigm

Categories: News